The latest NSCLC data presented at ELCC 2025

2 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this conference highlights video, Prof. Nicolas Girard shares his perspectives on the latest data for oncogene-addicted non-small cell lung cancer (NSCLC) from ELCC 2025.

Prof. Girard reviews data from the following studies: 

- SOHO-01: Phase 1/2 SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts. Girard N, et al. Abstract 3O, ELCC 2025

- MARIPOSA: Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: Final overall survival from the Phase 3 MARIPOSA study. Chih-Hsin Yang J, et al. Abstract 4O, ELCC 2025

- COCOON: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial. Girard N, et al. Abstract 10MO, ELCC 2025

- SAVANNAH: Savolitinib + osimertinib in patients with EGFRm advanced NSCLC and MET overexpression and/or amplification following progressive disease on osimertinib. Ahn M-J, et al. Abstract 2O, ELCC 2025

- ORCHARD: Osimertinib + datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC whose disease progressed on first-line osimertinib: ORCHARD. Le X, et al. Abstract 1O, ELCC 2025

- DESTINY-Lung03: Phase 1b open-label study of trastuzumab deruxtecan + rilvegostomig ± carboplatin as first-line treatment for metastatic HER2-overexpressing NSCLC: DESTINY-Lung03 (DL-03) Part 4. Planchard D, et al. 132TiP, ELCC 2025


Follow LUNG CONNECT on:

X – https://x.com/lung_connect

LinkedIn – https://www.linkedin.com/company/lungconnect/



This content is intended for healthcare professionals only.

The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by an Independent Education Grant from Bayer.



This video is developed by cor2ed.com

Published April 2024



Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Category
Oncology
Be the first to comment

Up Next